AU7596496A - Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia - Google Patents

Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia

Info

Publication number
AU7596496A
AU7596496A AU75964/96A AU7596496A AU7596496A AU 7596496 A AU7596496 A AU 7596496A AU 75964/96 A AU75964/96 A AU 75964/96A AU 7596496 A AU7596496 A AU 7596496A AU 7596496 A AU7596496 A AU 7596496A
Authority
AU
Australia
Prior art keywords
conjugation
cholesterol
inhibitory effect
antisense oligonucleotides
significantly enhance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU75964/96A
Inventor
Angelica Fleser
Guy Leclerc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Interventional Systems Co
Original Assignee
Johnson and Johnson Interventional Systems Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Interventional Systems Co filed Critical Johnson and Johnson Interventional Systems Co
Publication of AU7596496A publication Critical patent/AU7596496A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU75964/96A 1995-10-19 1996-10-18 Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia Abandoned AU7596496A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US554495P 1995-10-19 1995-10-19
US005544 1995-10-19
US1203796P 1996-02-21 1996-02-21
US012037 1996-02-21
PCT/US1996/016796 WO1997014440A1 (en) 1995-10-19 1996-10-18 Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia

Publications (1)

Publication Number Publication Date
AU7596496A true AU7596496A (en) 1997-05-07

Family

ID=26674475

Family Applications (1)

Application Number Title Priority Date Filing Date
AU75964/96A Abandoned AU7596496A (en) 1995-10-19 1996-10-18 Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia

Country Status (3)

Country Link
AU (1) AU7596496A (en)
CA (1) CA2241835A1 (en)
WO (1) WO1997014440A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation
EP1432450B1 (en) 2001-10-03 2005-12-28 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US20060135455A1 (en) 2004-06-01 2006-06-22 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
WO2007064857A2 (en) 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Amphoteric liposome formulation
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2153158A1 (en) * 1993-01-07 1994-07-21 Andrew Zalewski Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells
NZ265555A (en) * 1993-04-19 1997-09-22 Medisorb Technologies Internat Biodegradable microparticle compositions of antisense oligodeoxyribonucleotides
AU4923696A (en) * 1995-02-10 1996-08-27 Nexstar Pharmaceuticals, Inc. Lipid constructs for cytoplasmic delivery of agents

Also Published As

Publication number Publication date
WO1997014440A1 (en) 1997-04-24
CA2241835A1 (en) 1997-04-24

Similar Documents

Publication Publication Date Title
AU5317496A (en) Single-stranded circular oligonucleotides
AU3222795A (en) Antitumor antisense oligonucleotides
AU9023798A (en) Mdm2-specific antisense oligonucleotides
AU6973296A (en) Beta-substituted organosilsesquioxanes and use thereof
AU5968796A (en) Triple-helix forming oligonucleotides for targeted mutagenes is
AU5160796A (en) Dual action syringe
AU6602196A (en) Electrode catheter
AU6513096A (en) Treatment of fabrics
AU5441896A (en) Cooperative oligonucleotides
AU5788396A (en) Methods of inhibition or killing of cancer cells
AU4983396A (en) Inhibition of proliferation of vascular smooth muscle cell
AU7073096A (en) Inhibited biological degradation of oligodeoxynucleotides
AU5259498A (en) Antisense oligonucleotides
GB9505438D0 (en) Antisense oligonucleotides
AU5122796A (en) Amidite derivatives and oligonucleotide derivatives
AU1279397A (en) Modified vegf antisense oligonucleotides
AU1564897A (en) Antisense inhibition of human adhesion molecules
AU1184399A (en) Therapeutic molecules
AU5656796A (en) Use of sesquiterpenes for inhibiting oxidative enzymes
AU7596496A (en) Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia
AU3555295A (en) Game of chance
AU2585197A (en) Antisense approach to gene inhibition
IL143499A0 (en) Liposomic niflumic acid-new transdermal anti-inflammatory medicine
GB9713332D0 (en) Interleaved and sequential counter
AU7000496A (en) Anti-inflammatory antisense drug